Network Meta-analysis of oral Chinese patent medicines in treatment of acute exacerbation of chronic obstructive pulmonary disease.
10.19540/j.cnki.cjcmm.20230226.501
- Author:
Meng-Yao DING
1
;
Shu-Guang YANG
2
;
Ning-Xia YU
1
;
Yun-Zhe HONG
1
;
Zi-Chun YE
1
;
Xue-Qing YU
3
Author Information
1. Henan University of Chinese Medicine Zhengzhou 450046, China.
2. the First Affiliated Hospital of Henan University of Chinese Medicine Zhengzhou 450000, China.
3. Henan University of Chinese Medicine Zhengzhou 450046, China the First Affiliated Hospital of Henan University of Chinese Medicine Zhengzhou 450000, China.
- Publication Type:Journal Article
- Keywords:
acute exacerbation of chronic obstructive pulmonary disease;
network Meta-analysis;
oral Chinese patent medicine
- MeSH:
Humans;
Capsules;
Network Meta-Analysis;
Pulmonary Disease, Chronic Obstructive/drug therapy*;
Medicine, Chinese Traditional
- From:
China Journal of Chinese Materia Medica
2023;48(12):3373-3385
- CountryChina
- Language:Chinese
-
Abstract:
This study aimed to evaluate the effectiveness and safety of eight oral Chinese patent medicines in the treatment of acute exacerbation of chronic obstructive pulmonary disease(AECOPD) by network Meta-analysis. Randomized controlled trial(RCT) on the treatment of AECOPD with eight oral Chinese patent medicines was retrieved from databases including CNKI, Wanfang, VIP, SinoMed, PubMed, Web of Science, EMbase, and Cochrane Library from database inception to August 6, 2022. The information was extracted from the included literature and the quality of the included studies was evaluated using the Cochrane risk of bias assessment tool. The data were analyzed using Stata SE 15.1 and ADDIS 1.16.8 software. Finally, 53 RCTs were included, with 5 289 patients involved, including 2 652 patients in the experimental group and 2 637 patients in the control group. Network Meta-analysis showed that Lianhua Qingwen Capsules+conventional western medicine were optimal in improving clinical effective rate, Shufeng Jiedu Capsules+conventional western medicine in improving FEV1/FVC, Qingqi Huatan Pills+conventional western medicine in improving FEV1%pred, Feilike Mixture(Capsules)+conventional western medicine in improving PaO_2, Lianhua Qingwen Capsules+conventional western medicine in reducing PaCO_2, and Qingqi Huatan Pills+conventional western medicine in reducing C-reactive protein(CRP). In terms of safety, most of them were gastrointestinal symptoms, and no serious adverse reactions were reported. When the clinical effective rate was taken as the comprehensive index of efficacy evaluation, Lianhua Qingwen Capsules+conventional western medicine were the most likely to be the best treatment for AECOPD. There are some limitations in the conclusion of this study. It only provides references for clinical medication.
